Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
Piers Blombery, Ella R. Thompson, Tamia Nguyen, Richard W. Birkinshaw, Jianan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F. Seymour, David Westerman, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts
Abstract
The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic lymphocytic leukemia patients, but secondary resistance reflecting acquired mutations in BCL2 can lead to treatment failure. Blombery et al report that an unexpectedly large number of patients carry multiple BCL2 mutations with subclonal variation in their occurrence.
Topics & Concepts
VenetoclaxChronic lymphocytic leukemiaLeukemiaMedicineImmunologyMutationCancer researchOncologyInternal medicineBiologyGeneticsGeneChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsLymphoma Diagnosis and Treatment